All News

FcRH5 is emerging as a potentially highly active target for cellular therapies in multiple myeloma care, said Natalia Neparidze, MD.

Julian Hong, MD, MS, discussed an analysis showing that patients with cancer and new mental health disorders have an increased risk of all-cause mortality.

According to a study published in Cancer, new-onset mental health disorders increased the risk of all-cause mortality in patients with cancer.

Adverse effects of novel immunotherapies appear controllable compared with chemotherapy in hematologic malignancies, according to Guenther Koehne, MD.

Results from a phase 1b trial for givastomig in front-line HER2-negative, PD-L1–positive gastroesophageal cancer support the FDA’s decision.

Emergent phase 1 LuPARP study data suggest that metastatic castration-resistant prostate cancer could be treated with PARP inhibition and radionuclides.

Over the past 40 years, oncology shifted to precision care, smarter toxicity management, AI-guided guidelines, and equity, according to Julie Gralow, MD.

Newer generations of BTK inhibitors may have fewer cardiac toxicities compared with earlier iterations, according to Nicole Lamanna, MD.

The updated NDA to the FDA included additional data and statistical analyses from existing clinical trials for pediatric and adult patients with glioma.

Twenty patients with low-to-intermediate risk, localized prostate cancer underwent successful implantation with the anti-androgen eluting implants.

Based on an independent data monitoring committee’s feedback, enrollment for the phase 3 TACTI-004 trial will be halted.

Lynette Fernandez-Cuesta, PhD, discussed how the Petersen Accelerator Grant will drive the development of real-time clinical biomarkers for aggressive lung NETs.

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

The addition of SBRT to an immunotherapy doublet did not significantly affect safety outcomes among patients with de novo metastatic RCC.

Julia E. McGuiness, MD, discussed the timeline for mammographic density changes following significant weight loss.

Scott Tagawa, MD, MS, FACP, FASCO, evaluated how the rPFS improvement with lutetium 177 could help integrate the treatment into the frontline metastatic HSPC setting.

Treatment with rusfertide appears to reliably control hematocrit among those with polycythemia vera, according to Andrew Kuykendall, MD.

The adoption of bispecific antibodies in the community setting remains a great unmet need in multiple myeloma, according to Rajshekhar Chakraborty, MD.

Oliver Sartor, MD highlighted SBRT, hormonal therapy, and the PSMA-DC regimen for patients with biochemical recurrence and PSMA-PET–positive disease.

Yan Leyfman, MD, discussed the factors that may ultimately define the next era of transplant medicine across hematologic malignancies.

Among patients who discontinued enfortumab vedotin due to an ongoing response or toxicity, 57% were treatment-free and alive 1 year later.

Integrating a medically supervised ketogenic diet with gemcitabine, nab-paclitaxel, and cisplatin significantly extends OS in those with metastatic PDAC.

Acalabrutinib/venetoclax may offer less toxicity compared with other therapies in chronic lymphocytic leukemia, said Nicole Lamanna, MD.

Key takeaways from the 43rd Miami Breast Cancer Conference focused on managing oligometastatic and oligoprogressive breast cancer with metastasis-directed therapy.

Gary L. Clayman, DMD, MD, FACS, discussed evaluating the link between GLP-1 receptor agonists and thyroid cancer.

According to Sebnem Ece Eksi, PhD, sympathetic signals led to shifts in cancer-associated fibroblasts to a more inflammatory state.

The future of radiation oncology will be largely affected by artificial intelligence and genomics, according to Sheila D. Rege, MD, FACRO.

By harnessing investigator-generated data, companion diagnostics, and biomarker-directed treatment selection, clinicians can optimize care for HSPC.

Zolucatetide yielded a DCR of 100% and ORR of 80% among patients with secretase-naive and secretase-treated desmoid tumors.

According to Brian Henick, MD, understanding why certain patients experience specific AEs will be key for giving more precise lung cancer therapy.